Lung cancer driver ALK-fusion found in melanoma

October 23, 2017

Melanomas caused by sun exposure have been matched with targeted treatments and immunotherapies, in many cases dramatically extending patients' lives. However, there are other kinds of melanoma not related to sun exposure and because they are caused by different genetic changes, they are not susceptible to the same targeted treatments. This often leaves patients with these non-sun melanoma subtypes without treatment options. A University of Colorado Cancer Center study published today in the journal Molecular Cancer Therapeutics may offer hope to some of these patients with melanomas caused by genetic changes not related to sun exposure. The study finds a genetic change called ALK-fusion in a patient sample of a melanoma subtype called mucosal melanoma. When researchers treated a tumor grown from this sample with the drugs crizotinib and ceritinib - both FDA approved to treat ALK-positive lung cancer - the tumor responded dramatically.

"Maybe these non-sun-exposed melanomas are molecularly more like a lung cancer or a colorectal cancer, and maybe we should be treating them like that," says Kasey Couts, PhD, assistant research professor at the CU School of Medicine, the paper's first author. Couts worked in the lab of CU Cancer Center investigator William Robinson, MD (a specialist in melanoma) and in collaboration with Robert C. Doebele, MD, PhD (a specialist in gene fusions).

The finding takes place in the context of growing awareness that the genetic changes that cause cancer may be shared across cancer types, and also that there are many ways these cancer-causing genes may be changed.

This study examined a specific kind of genetic change known as gene fusion in which partner genes that should sit in separate places on the genome are accidentally spliced next to each other in a way that creates a new "fusion protein". In this case, the gene ALK becomes fused with the gene EML4 to create the fusion gene EML4-ALK. This EML4-ALK fusion gene creates a protein that has been shown to cause a subset of non-small cell lung cancers, and has now been successfully targeted by a handful of FDA approved drugs.

The current study examined 45 melanoma patient samples, finding EML4-ALK fusion in one, a sample of a melanoma subtype called mucosal melanoma, a form of the disease unrelated to sun exposure that often arises on mucosal surfaces such as the sinonasal tract, perinium, and vulvovaginal areas. Sure enough, when the group treated EML4-ALK tumor samples with ALK inhibitors developed to treat ALK-positive lung cancer, the tumors responded.

"It seems like these melanomas that don't come from sun exposure may have fusions not seen in the more common form of the disease, and thus may be more susceptible to targeted treatments that attack these fusions than they are to drugs developed to treat other kinds of melanoma," Couts says.

Interestingly, the group also explored a closely related genetic change in the ALK gene previously reported as a driver and possible target in 11 percent of melanomas. Rather than ALK fusion, this other kind of change results in the manufacture of a protein closely related to ALK, called an ALK alternate transcript isoform (ALKATi), which is basically a shortened form of ALK. The earlier work implied that melanomas with ALKATi may respond to ALK inhibitors, but the current study refutes this claim, finding that inhibiting EML4-ALK fusion but not ALKATi results in the death of cancer cells. A patient expressing ALKATi who was treated on a phase I clinical trial with an ALK inhibitor did not respond.

"We don't think the isoform will be the target. We think the fusion will be," Couts says.

She also suggests that oncologists treating melanoma may consider the use of broad genomic profiling to search for gene fusions that may be driving specific melanomas.

"In this study, we found ALK-fusion. In a previous study, we found ROS1-fusion. It seems like especially in these non-sun-exposed melanomas that are most often driven by oncogenes not found in regular melanomas, multiplex screening could identify additional treatment options," Couts says, adding that any possible new treatments will have to be validated in the context of clinical trials.

Now the group continues to explore two major research directions, first continuing to show the rationale for the use of ALK-inhibitors to treat EML4-ALK fusion melanoma, and second exploring melanoma for additional genetic changes that may respond to targeted treatments.

University of Colorado Anschutz Medical Campus

Related Lung Cancer Articles from Brightsurf:

State-level lung cancer screening rates not aligned with lung cancer burden in the US
A new study reports that state-level lung cancer screening rates were not aligned with lung cancer burden.

The lung microbiome may affect lung cancer pathogenesis and prognosis
Enrichment of the lungs with oral commensal microbes was associated with advanced stage disease, worse prognosis, and tumor progression in patients with lung cancer, according to results from a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

New analysis finds lung cancer screening reduces rates of lung cancer-specific death
Low-dose CT screening methods may prevent one death per 250 at-risk adults screened, according to a meta-analysis of eight randomized controlled clinical trials of lung cancer screening.

'Social smokers' face disproportionate risk of death from lung disease and lung cancer
'Social smokers' are more than twice as likely to die of lung disease and more than eight times as likely to die of lung cancer than non-smokers, according to research presented at the European Respiratory Society International Congress.

Lung cancer therapy may improve outcomes of metastatic brain cancer
A medication commonly used to treat non-small cell lung cancer that has spread, or metastasized, may have benefits for patients with metastatic brain cancers, suggests a new review and analysis led by researchers at St.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Lung transplant patients face elevated lung cancer risk
In an American Journal of Transplantation study, lung cancer risk was increased after lung transplantation, especially in the native (non-transplanted) lung of single lung transplant recipients.

Proposed cancer treatment may boost lung cancer stem cells, study warns
Epigenetic therapies -- targeting enzymes that alter what genes are turned on or off in a cell -- are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant.

Are you at risk for lung cancer?
This question isn't only for people who've smoked a lot.

Read More: Lung Cancer News and Lung Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to